We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+38.56%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$47.5M
Cap. Flow
-$5.93M
Cap. Flow %
-2.6%
Top 10 Hldgs %
58.57%
Holding
49
New
15
Increased
12
Reduced
11
Closed
11
Avg Time Held Equity + Options
2.7 quarters
Top 10 Avg Time Held Equity + Options
2.2 quarters
Top 20 Avg Time Held Equity + Options
2.8 quarters
Avg Time Held Equity only
3 quarters
Top 10 Avg Time Held Equity only
2.2 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$7.8M
2
ANAB icon
AnaptysBio
ANAB
+$5.55M
3
NVST icon
Envista
NVST
+$4.69M
4
ORGO icon
Organogenesis Holdings
ORGO
+$3.92M
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.69M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17M
2
HNGR
Hanger Inc.
HNGR
+$8.05M
3
QURE icon
uniQure
QURE
+$5.02M
4
HUM icon
Humana
HUM
+$3.07M
5
ABBV icon
AbbVie
ABBV
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.18%
2 Miscellaneous 3.98%
3 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EVH icon
26
Evolent Health
EVH
$525M
$2.53M 1.11%
+279,390
New +$2.27M
2019 Q4
0 quarters
CI icon
27
Cigna
CI
$75.9B
$2.31M 1.01%
11,293
+293
+3% +$53.7K
2018 Q1
7 quarters
MTEM icon
28
DELISTED
Molecular Templates, Inc.
MTEM
$2.25M 0.99%
10,726
-4,140
-28% -$595K
2019 Q1
3 quarters
CUE icon
29
Cue Biopharma
CUE
$138M
$2.19M 0.96%
+4,588
New +$1.44M
2019 Q4
0 quarters
ALLK icon
30
PUT
DELISTED
Allakos
ALLK
$1.97M 0.87%
+20,700
New +$1.82M
2019 Q4
0 quarters
PRTK
31
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.81M 0.8%
+450,000
New +$1.56M
2019 Q4
0 quarters
TNET icon
32
TriNet
TNET
$3.04B
$1.59M 0.7%
+28,104
New +$1.56M
2019 Q4
0 quarters
KZR icon
33
DELISTED
Kezar Life Sciences
KZR
$1.28M 0.56%
+32,000
New +$985K
2019 Q4
0 quarters
TLGT
34
DELISTED
Teligent, Inc
TLGT
$632K 0.28%
148,453
-96,151
-39% -$597K
2018 Q1
7 quarters
AXSM icon
35
PUT
Axsome Therapeutics
AXSM
$8.41B
$620K 0.27%
+6,000
New +$242K
2019 Q4
0 quarters
MIST icon
36
Milestone Pharmaceuticals
MIST
$98.2M
$616K 0.27%
+38,481
New +$681K
2019 Q4
0 quarters
BMY icon
37
Bristol-Myers Squibb
BMY
$119B
$520K 0.23%
8,100
-296,800
-97% -$17M
2019 Q1
3 quarters
APEN
38
DELISTED
Apollo Endosurgery, Inc.
APEN
$454K 0.2%
+159,336
New +$461K
2019 Q4
0 quarters
ABBV icon
39
AbbVie
ABBV
$501B
– –
-39,000
Closed -$2.95M –
ADMA icon
40
ADMA Biologics
ADMA
$2.35B
– –
-548,409
Closed -$2.44M –
GH icon
41
Guardant Health
GH
$22B
– –
-41,700
Closed -$2.66M –
HUM icon
42
Humana
HUM
$51.3B
– –
-12,000
Closed -$3.07M –
TPST icon
43
Tempest Therapeutics
TPST
$11M
– –
-267
Closed -$370K –
QTTB icon
44
Q32 Bio
QTTB
$240M
– –
-8,517
Closed -$2.77M –
RETA
45
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-12,300
Closed -$988K –
CLVS
46
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-587,626
Closed -$2.31M –
HNGR
47
DELISTED
Hanger Inc.
HNGR
– –
-395,000
Closed -$8.05M –
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-59,168
Closed -$924K –
UROV
49
DELISTED
Urovant Sciences Ltd.
UROV
– –
-102,657
Closed -$972K –
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q4 2019 Portfolio in Review

As of Q4 2019, Prosight Management held 49 positions worth $228M, up 26% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management's Q4 2019 filing shows 15 new, 12 increased, 11 reduced and 11 closed positions. Its largest new stake was AnaptysBio: 234,823 shares worth $3.82M. The largest sale was Bristol-Myers Squibb, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • Prosight Management's largest Q4 2019 buy was AnaptysBio: 234,823 shares worth $3.82M.
  • Prosight Management added most to Arena Pharmaceuticals Inc in Q4 2019, an estimated $7.8M increase.
  • Prosight Management's biggest Q4 2019 reduction was Bristol-Myers Squibb, cutting an estimated $17M.
  • Prosight Management fully exited Hanger Inc. in Q4 2019, selling an estimated $8.05M.
  • Prosight Management's ten largest holdings make up 59% of its $228M portfolio in Q4 2019.
  • Prosight Management opened 15 new positions and closed 11 in Q4 2019.
  • Prosight Management's portfolio value rose 26% quarter-over-quarter to $228M.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.